These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30542286)

  • 1. Biomodulatory Treatment With Azacitidine, All-
    Klobuch S; Steinberg T; Bruni E; Mirbeth C; Heilmeier B; Ghibelli L; Herr W; Reichle A; Thomas S
    Front Pharmacol; 2018; 9():1380. PubMed ID: 30542286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation.
    Iriyama N; Yuan B; Hatta Y; Takagi N; Takei M
    Cancer Cell Int; 2016; 16():37. PubMed ID: 27182202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-aminoimidazole-4-carboxamide ribonucleoside induces differentiation in a subset of primary acute myeloid leukemia blasts.
    Dembitz V; Lalic H; Kodvanj I; Tomic B; Batinic J; Dubravcic K; Batinic D; Bedalov A; Visnjic D
    BMC Cancer; 2020 Nov; 20(1):1090. PubMed ID: 33176741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
    Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
    Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML.
    Heudobler D; Klobuch S; Thomas S; Hahn J; Herr W; Reichle A
    Front Pharmacol; 2018; 9():1279. PubMed ID: 30483125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment.
    Su M; Alonso S; Jones JW; Yu J; Kane MA; Jones RJ; Ghiaur G
    PLoS One; 2015; 10(6):e0127790. PubMed ID: 26047326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigallocatechin-3-gallate induces cell death in acute myeloid leukaemia cells and supports all-trans retinoic acid-induced neutrophil differentiation via death-associated protein kinase 2.
    Britschgi A; Simon HU; Tobler A; Fey MF; Tschan MP
    Br J Haematol; 2010 Apr; 149(1):55-64. PubMed ID: 20096012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression.
    Bradbury DA; Aldington S; Zhu YM; Russell NH
    Br J Haematol; 1996 Sep; 94(4):671-5. PubMed ID: 8826891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the relationship between Scl transcription factor complex protein expression patterns and the effects of LiCl on ATRA-induced differentiation in blast cells from patients with acute myeloid leukemia.
    Rice AM; Holtz KM; Karp J; Rollins S; Sartorelli AC
    Leuk Res; 2004 Nov; 28(11):1227-37. PubMed ID: 15380350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy.
    Kattner AS; Holler E; Herr W; Reichle A; Wolff D; Heudobler D
    Front Oncol; 2020; 10():443. PubMed ID: 32391254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.
    Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
    Clin Cancer Res; 2016 Mar; 22(5):1211-21. PubMed ID: 26459180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia.
    Miyauchi J
    Leuk Lymphoma; 1999 Apr; 33(3-4):267-80. PubMed ID: 10221506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Bromodomain Inhibitor JQ1 Enhances the Responses to All-
    Kang C; Kim CY; Kim HS; Park SP; Chung HM
    Int J Stem Cells; 2018 May; 11(1):131-140. PubMed ID: 29699387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
    Belhabri A; Thomas X; Wattel E; Chelghoum Y; Anglaret B; Vekhoff A; Reman O; Dombret H; Dhedin N; Michallet M; Fière D; Archimbaud E
    Hematol J; 2002; 3(1):49-55. PubMed ID: 11960396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia.
    Thomas S; Schelker R; Klobuch S; Zaiss S; Troppmann M; Rehli M; Haferlach T; Herr W; Reichle A
    Haematologica; 2015 Jan; 100(1):e4-6. PubMed ID: 25261094
    [No Abstract]   [Full Text] [Related]  

  • 17. Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas.
    Zang C; Wächter M; Liu H; Posch MG; Fenner MH; Stadelmann C; von Deimling A; Possinger K; Black KL; Koeffler HP; Elstner E
    J Neurooncol; 2003 Nov; 65(2):107-18. PubMed ID: 14686729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
    Pleyer L; Döhner H; Dombret H; Seymour JF; Schuh AC; Beach CL; Swern AS; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy.
    Wu W; Lin Y; Xiang L; Dong W; Hua X; Ling Y; Li H; Yan F; Xie X; Gu W
    Ann Hematol; 2016 Jun; 95(7):1051-7. PubMed ID: 27116384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All-trans retinoic acid as a single agent induces complete remission in a patient with acute leukemia of M2a subtype.
    Chen Z; Wang Y; Wang W; Gong J; Xue Y
    Chin Med J (Engl); 2002 Jan; 115(1):58-61. PubMed ID: 11930660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.